Am I Eligible for Mounjaro? Edinburgh Eligibility Guide

Whether you are eligible for Mounjaro depends on two things: your BMI, and whether you have any weight-related health conditions that lower the threshold. For most patients, the answer becomes clear within minutes of reviewing the criteria. What matters is that the eligibility assessment is a clinical conversation, not an automated screening tool — and that if you are unsure, a consultation is the right next step rather than a reason to delay.

At Bruntsfield Pharmacy, our Independent Prescriber pharmacists conduct a thorough eligibility assessment at every first consultation. No GP referral is required. This guide explains the clinical criteria, what the assessment involves, which conditions can affect your eligibility, and who is not suitable for Mounjaro. For the full treatment overview, see our complete guide to Mounjaro in Edinburgh.

The clinical eligibility criteria for Mounjaro

Mounjaro (tirzepatide) is licensed in the UK for chronic weight management in adults. The MHRA-approved eligibility criteria mirror those used in the SURMOUNT clinical trials and set a clear threshold based on BMI and the presence of weight-related health conditions.

If you are unsure of your BMI, your pharmacist will calculate it at the consultation. A BMI of 27 is the point at which excess weight is considered to begin carrying meaningful clinical risk when accompanied by a related health condition — which is why the threshold is lower for patients in this group.

Weight-related conditions that can lower the eligibility threshold

For patients with a BMI between 27 and 29.9 — technically classified as overweight rather than obese — Mounjaro is still available if at least one of the following conditions is present. These are conditions where excess weight is known to be a contributing factor and where weight loss is likely to produce meaningful clinical benefit beyond the number on the scales.

Type 2 diabetes

Mounjaro has a dual mechanism relevant to type 2 diabetes — it improves insulin sensitivity and reduces blood glucose independently of its weight loss effect. In SURMOUNT-2, patients with type 2 diabetes lost an average of 15.7% of their body weight at the 15mg dose, with significant improvements in HbA1c. For patients on diabetes medication, your prescriber will review potential interactions and may advise on dose adjustments to existing treatments.

High blood pressure (hypertension)

Excess weight is one of the most significant modifiable risk factors for hypertension. Weight loss through Mounjaro has been shown in clinical trials to reduce systolic blood pressure meaningfully — in some cases to the point where patients are able to reduce antihypertensive medication under clinical supervision.

High cholesterol (dyslipidaemia)

Mounjaro has demonstrated favourable effects on lipid profiles in clinical trials, including reductions in LDL cholesterol and triglycerides. Patients with elevated cholesterol levels alongside overweight often see meaningful improvements in their lipid markers alongside weight loss.

Obstructive sleep apnoea

Excess weight around the neck and upper airway is a primary driver of obstructive sleep apnoea. Substantial weight loss — of the kind Mounjaro produces — can significantly reduce the severity of sleep apnoea and in some cases resolve it altogether, reducing reliance on CPAP therapy.

Cardiovascular disease

Patients with established cardiovascular disease and a BMI of 27 or above are eligible for Mounjaro. The SURMOUNT-CVOT trial demonstrated a statistically significant reduction in major adverse cardiovascular events in this patient group, making Mounjaro one of the few weight loss medications with direct cardiovascular outcome data.

Polycystic ovary syndrome (PCOS)

PCOS is not listed as a named qualifying condition in the Mounjaro licence, but it is a recognised weight-related condition associated with insulin resistance, and patients with PCOS who also have hypertension, dyslipidaemia, or type 2 diabetes will meet the eligibility criteria on those grounds. Your pharmacist will review your full clinical history at the consultation.

Who is not suitable for Mounjaro?

There are specific contraindications to Mounjaro that your pharmacist will review at the consultation. If any of these apply, Mounjaro will not be prescribed — and your pharmacist will discuss alternatives including Wegovy (semaglutide), where appropriate.

If you have type 2 diabetes and are taking insulin or a sulphonylurea, you may still be eligible — but your prescriber will need to review your current medications carefully, as dose adjustments may be necessary to avoid hypoglycaemia.

What the eligibility assessment involves

The assessment at Bruntsfield Pharmacy is conducted by a qualified Independent Prescriber pharmacist. It is thorough, unhurried, and designed to give you a clear answer — either a prescription and your first pen, or an honest explanation of why Mounjaro is not the right option and what is available instead.

1. Pre-appointment questionnaire — completed online before your visit, covering weight history, medical conditions, and current medications.
2. In-person review — your pharmacist confirms your BMI, reviews your health history, checks for contraindications and relevant drug interactions, and answers your questions.
3. Prescription and supply — if Mounjaro is clinically appropriate, your private prescription is issued and your first pen dispensed at the same appointment. Injection training is included.
4. Ongoing monitoring — dose escalation reviews at each 4-week step up, with access to the clinical team between appointments.

Book your Mounjaro consultation in Edinburgh

Mounjaro eligibility — your questions answered